SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Thomas J. van ‘t Erve, Fred B. Lih, Maria B. Kadiiska, Leesa J. Deterding, Thomas E. Eling, Ronald P. Mason, Reinterpreting the best biomarker of oxidative stress: The 8-iso-PGF2α / PGF2α ratio Distinguishes chemical from enzymatic lipid peroxidation, Free Radical Biology and Medicine, 2015,

    CrossRef

  2. 2
    Reinhard W. Hoffmann, Natural Product Synthesis: Changes over Time, Angewandte Chemie International Edition, 2013, 52, 1
  3. 3
    Reinhard W. Hoffmann, Naturstoffsynthese im Wandel der Zeit, Angewandte Chemie, 2013, 125, 1
  4. 4
    R. Igarashi, Y. Mizushima, New lipo-PGE1 using a stable prodrug of prostaglandin E1 (PGE1), Advanced Drug Delivery Reviews, 1996, 20, 2-3, 189

    CrossRef

  5. 5
    Y. Mizushima, K. Hoshi, Review: Recent Advances in Lipid Microsphere Technology for Targeting Prostaglandin Delivery, Journal of Drug Targeting, 1993, 1, 2, 93

    CrossRef

  6. 6
    R. Igarashi, Y. Mizushima, M. Takenaga, K. Matsumoto, Y. Morizawa, A. Yasuda, A stable PGE1 prodrug for targeting therapy, Journal of Controlled Release, 1992, 20, 1, 37

    CrossRef

  7. 7
    Paul W. Collins, Misoprostol: Discovery, development, and clinical applications, Medicinal Research Reviews, 1990, 10, 2
  8. 8
    Stephen J. Kirtland, Prostaglandin E1: A review, Prostaglandins, Leukotrienes and Essential Fatty Acids, 1988, 32, 3, 165

    CrossRef

  9. 9
    Ute Hofmann, Claus O. Meese, Markus Hecker, Volker Ullrich, Synthesis of novel prostaglandin F2α isomers and structure of an enzymatically formed 13-hydroxyprostaglandin endoperoxide, Tetrahedron Letters, 1987, 28, 46, 5655

    CrossRef

  10. 10
    Bengt Samuelsson, From studies of biochemical mechanism to novel biological mediators: Prostaglandin endoperoxides, thromboxanes, and leukotriences, Bioscience Reports, 1983, 3, 9, 791

    CrossRef

  11. 11
    Bengt Samuelsson, From Studies of Biochemical Mechanism to Novel Biological Mediators: Prostaglandin Endoperoxides, Thromboxanes, and Leukotrienes (Nobel Lecture), Angewandte Chemie International Edition in English, 1983, 22, 11
  12. 12
    Bengt Samuelsson, Von Untersuchungen biochemischer Mechanismen zu neuen biologischen Mediatoren: Prostaglandinendoperoxide, Thromboxane und Leukotriene (Nobel-Vortrag), Angewandte Chemie, 1983, 95, 11
  13. 13
    Wilhelm Bartmann, Gerhard Beck, Prostacyclin und synthetische Analoga, Angewandte Chemie, 1982, 94, 10
  14. 14
    Walter O. Lundberg, On the Quantification of Essential Fatty Acid Requirements, Fette, Seifen, Anstrichmittel, 1979, 81, 9
  15. 15
    Tawfik M. A. ElAttar, Prostaglandins: physiology, biochemistry, pharmacology and clinical applications, Journal of Oral Pathology & Medicine, 1978, 7, 5
  16. 16
    Pierre Crabbé, Prostaglandin Research, 1977,

    CrossRef

  17. 17
    Wilhelm Bartmann, Prostaglandine, Angewandte Chemie, 1975, 87, 5
  18. 18
    Wilhelm Bartmann, Prostaglandins, Angewandte Chemie International Edition in English, 1975, 14, 5
  19. 19
    T. O. Oesterling, W. Morozowich, T. J. Roseman, Prostaglandins, Journal of Pharmaceutical Sciences, 1972, 61, 12
  20. 20
    M.P.L. Caton, The Prostaglandins, 1972,

    CrossRef

  21. 21
    P.W. Ramwell, J.E. Shaw, G.B. Clarke, M.F. Grostic, D.G. Kaiser, J.E. Pike, Prostaglandins, Progress in the Chemistry of Fats and other Lipids, 1971, 9, 231

    CrossRef

  22. 22
    L.S. WOLFE, Fundamentals of Biochemical Pharmacology, 1971,

    CrossRef

  23. 23
    Fundamentals of Biochemical Pharmacology, 1971,

    CrossRef

  24. 24
    M.P.L. Caton, 1971,

    CrossRef

  25. 25
    The Pharmacology of Synapses, 1970,

    CrossRef

  26. 26
    Bengt Samuelsson, Lipid Metabolism, 1970,

    CrossRef

  27. 27
    J. Kloeze, Relationship between chemical structure and plateletaggregation activity of prostaglandins, Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1969, 187, 3, 285

    CrossRef

  28. 28
    G.P. Ellis, 1969,

    CrossRef

  29. 29
    S.N.M. Karim, K. Hillier, A sensitive method for the assay of prostaglandins E1, E2, F1α and F2α, European Journal of Pharmacology, 1968, 4, 2, 205

    CrossRef

  30. 30
    S. M. M. KARIM, K. HILLIER, JEAN DEVLIN, Distribution of prostaglandins E1, E2, F1α and F2α, in some animal tissues, Journal of Pharmacy and Pharmacology, 1968, 20, 10
  31. 31
    L.A. Carlson, E. Irion, L. Orö, Effect of infusion of prostaglandin E1 on the aggregation of blood platelets in man, Life Sciences, 1968, 7, 1, 85

    CrossRef

  32. 32
    C.Ward Kischer, Effects of specific prostaglandins on development of chick embryo skin and down feather organ, in vitro, Developmental Biology, 1967, 16, 3, 203

    CrossRef

  33. 33
    A. Bizzi, E. Veneroni, S. Garattini, L. Puglisi, R. Paoletti, Hypersensitivity to lipid mobilizing agents in essential fatty acid (EFA) deficient rats, European Journal of Pharmacology, 1967, 2, 1, 48

    CrossRef

  34. 34
    G. L. AVANZINO, P. B. BRADLEY, J. H. WOLSTENCROFT, ACTIONS OF PROSTAGLANDINS E1, E2, AND F2a ON BRAIN STEM NEURONES, British Journal of Pharmacology and Chemotherapy, 1966, 27, 1
  35. 35
    SUNE BERGSTRÖM, Proceedings of the 1965 Laurentian Hormone Conference, 1966,

    CrossRef

  36. 36
    U. Axen, J. E. Pike, W. P. Schneider, The Total Synthesis of Prostaglandins,